MedWatch

Analyst predicts favorable market conditions for Coloplast

Advantageous market conditions for the Danish medtech firm, which has established a new division in its organization, will manifest as positive growth in the second quarter, says a Sydbank analyst.

Analyst Søren Løntoft Hansen has a bag full of positive predictions for Coloplast's upcoming quarterly report | Photo: Coloplast / PR

A general improvement in the market conditions for Danish medtech firm Coloplast’s divisions, Ostomy and Continence care, in addition to a contribution from the new business area dubbed Voice & Respiratory Care, will have a positive impact on Coloplast’s second quarterly report, according to Søren Løntoft Hansen, senior equity analyst at Sydbank.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs